Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions

CONCLUSIONS AND RELEVANCE: In Mali, long-acting monoclonal antibody is likely to be cost-effective from both the government and donor perspectives at $3 per dose. Maternal vaccine would need higher efficacy over that measured by a recent trial in order to be considered cost-effective.PMID:34325934 | DOI:10.1016/j.vaccine.2021.06.086

Source: Vaccine - July 30, 2021 Category: Allergy & Immunology Authors: Rachel S Laufer Amanda J Driscoll Ranju Baral Andrea G Buchwald James D Campbell Flanon Coulibaly Fatoumata Diallo Moussa Doumbia Alison P Galvani Fadima C Haidara Karen L Kotloff Adama M Keita Kathleen M Neuzil Evan W Orenstein Lauren A V Orenstein Clint Source Type: research